Lithium Carbonate Treatment in Manic Psychosis

Watanabe, Shinta; Taguchi, Kohji; Nakaya, Koji; Noma, T; Yokoyama, Shoji

doi:10.1111/j.1440-1819.1973.tb00096.x

Cited by 4 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since Glesinger's report,53 there are many uncontrolled studies reporting the effectiveness of lithium for schizophrenia, and in Japan Watanabe et a1. 165 have also reported.…”

Section: A Effects On Schizophreniamentioning

confidence: 86%

Lithium Ion and Affective Psychoses

Watanabe

Ishino

Otsuki

1974

Psychiatry Clin Neurosci

Self Cite

View full text Add to dashboard Cite

“…Since Glesinger's report,53 there are many uncontrolled studies reporting the effectiveness of lithium for schizophrenia, and in Japan Watanabe et a1. 165 have also reported.…”

Section: A Effects On Schizophreniamentioning

confidence: 86%

Lithium Ion and Affective Psychoses

Watanabe

Ishino

Otsuki

1974

Psychiatry Clin Neurosci

Self Cite

View full text Add to dashboard Cite

“…The range of therapeutically effective serum concentration of Li in Japan has been reported to bc between 0.4 and 1.0 mEq/1 (Watanahe et al , 1973) for treatment of moderately and severely ill manic patients. In a previous double-blind comparison study of Li and CPZ in Japan with a multi-institutional design similar to the present one (Takahashi et al, 1975), the mean daily dosage of Li was 1108 mg and the serum level of Li was 0.57 ± 0.30 mEq/l, and the percentage of patients who showed marked improvement was 32.4 % with 67.6 'x, showing marked and moderate improvement rates.…”

Section: Dosage Serum Concentration and Therapeutic Ejject Ojcarbammentioning

confidence: 99%

Comparison of the Antimanic Efficacy of Carbamazepine and Lithium Carbonate by Double-Blind Controlled Study

et al. 1990

View full text Add to dashboard Cite

A multi-institutional study comparing the antimanic effect of carbamazepine (CBZ) and lithium carbonate (Li) was performed using a double-blind group comparison design in a series of 105 patients with bipolar disorders. CBZ and Li were given for four weeks using a fixed-flexible method at an equipotent dose ratio of 1:1, starting from an initial dosage of 400 mg with a maximum dosage of 1200 mg. The final global improvement rate, based on the number of cases showing moderate to marked amelioration of manic symptoms, was 62% in the CBZ group and 59% in the Li group, with no significant difference being found between the two groups. Incidence of cutaneous side-effects was significantly higher in the CBZ group. The mean daily dosage and serum level of CBZ in the fourth week were 674 +/- 239 mg and 7.3 +/- 2.4 micrograms/ml respectively; these were within the therapeutic range. The daily dose and serum level of Li, however, were 710 +/- 239 mg and 0.46 +/- 0.22 mEq/l, and the Li level seemed to be too low to compare its therapeutic effect with that of CBZ. Prior to the present study, approximately 80% of the patients in both groups had been receiving antipsychotic medication, equivalent to 8.0 mg of haloperidol on average, without favorable response. This medication was maintained unchanged during treatment. While the shortcomings of the present study limit the interpretation of the data, it may be suggested that the usefulness of CBZ as a drug for the treatment of manic states is comparable to that of Li.

show abstract

“…So we have combined the measurements of serum Li with measurements of RBC Li concentration. Moreover we have carried out correlative studies by EMG (Girke et al, 1975;Pinelli et al, 1972) or EEG investigations (Zakowska-Dabrowska and Rybakowski, 1973;Johnson et al, 1970;Watanabe et al, 1973;Platman and Fieve, 1969).…”

Section: Introductionmentioning

confidence: 99%

Plasma and Erythrocyte Concentrations of Lithium

Zerbi¹,

Fenoglio²,

Tosca³

1975

Psychopathology

View full text Add to dashboard Cite

The authors have studied the clinical response, EMG and EEG changes in 12 depressed patients after 28 days of lithium carbonate treatment of 1,200 mg daily. The findings confirm: (1) a high correlation between the degree of improvement and the RBC lithium: plasma lithium ratio on the 28th day; (2) a slight decrease in motor conduction velocity (m.c.v.) and increase of M-response duration during lithium treatment; (3) no correlation between EEG and lithium levels and percentage of improvement.

show abstract

Lithium Carbonate Treatment in Manic Psychosis

Cited by 4 publications

References 36 publications

Lithium Ion and Affective Psychoses

Lithium Ion and Affective Psychoses

Comparison of the Antimanic Efficacy of Carbamazepine and Lithium Carbonate by Double-Blind Controlled Study

Plasma and Erythrocyte Concentrations of Lithium

Contact Info

Product

Resources

About